Table 2. Prevalence of Antiphospholipid Antibodies in Dallas Heart Study Population (N = 2427).
| aPL | No. positive (%) | |
|---|---|---|
| Manufacturer’s thresholda | Titer ≥40 units | |
| aCL IgGb | 26 (1.0) | 7 (0.3) |
| aCL IgMb | 156 (6.4) | 36 (1.5) |
| aCL IgA | 11 (0.5) | 6 (0.3) |
| aβ2GPI IgGb | 21 (0.9) | 10 (0.4) |
| aβ2GPI IgMb | 63 (2.6) | 26 (1.0) |
| aβ2GPI IgA | 62 (2.5) | 29 (1.2) |
| aPS/PT IgG | 18 (0.7) | 11 (0.5) |
| aPS/PT IgM | 88 (3.4) | 48 (2.0) |
| Any positive | 353 (14.5) | 153 (6.3) |
| Three positive aPL | 17 (0.7) | 2 (0.08) |
Abbreviations: aβ2GPI, anti–beta-2 glycoprotein I; aCL, anticardiolipin; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; aPS/PT, anti-phosphatidylserine/prothrombin.
a
Manufacturer’s thresholds: aCL IgG/M/A = 20 GPL/MPL/APL; aβ2GPI IgG/M/A = 20 SGU/SMU/SAU; aPS/PT IgG/M = 30 arbitrary units.
b
Antiphospholipid antibodies that are part of current APS classification criteria. Others are characterized as noncriteria aPL.